.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,820,643

« Back to Dashboard

Details for Patent: 7,820,643

Title:Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Abstract: The present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically acceptable salt thereof, wherein said dual serotonin norepinephrine reuptake inhibitor compound is characterized by a non-tricyclic structure and an equal or greater inhibition of norepinephrine reuptake than serotonin reuptake. In particular, the use of milnacipran to treat FMS, CFS, and pain is disclosed.
Inventor(s): Kranzler; Jay D. (La Jolla, CA), Rao; Srinivas G. (San Diego, CA)
Assignee: Cypress Bioscience, Inc. (San Diego, CA)
Filing Date:Jul 18, 2003
Application Number:10/623,431
Claims:1. A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof i) an effective amount of at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof; and ii) an effective amount of at least one additional compound selected from pregabalin, a pharmaceutically acceptable salt of pregabalin, or a combination thereof; with the proviso that the method excludes administering phenylalanine, tyrosine, or tryptophan.

2. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same dosage form.

3. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in separate dosage forms.

4. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered simultaneously.

5. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are administered separately.

6. The method of claim 2, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in the same oral dosage form.

7. The method of claim 3, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof and at least one additional compound are in separate oral dosage forms.

8. The method of claim 1, wherein the at least one compound selected from milnacipran, a pharmaceutically acceptable salt of milnacipran, or a combination thereof is in tablet form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc